Israel - English - Ministry of Health

a.l. medi-market ltd. - cefotaxime as sodium - powder for solution for inj/inf - cefotaxime as sodium 1 g/vial - cefotaxime - imetoxim 1 gr is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. septicaemiasrespiratory tract infections such as acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. urinary tract infections such as acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. soft-tissue infections such as cellulitis, peritonitis and wound infections. bone and joint infections such as osteomyelitis, septic arthritis. obstetric and gynaecological infections such as pelvic inflammatory disease. gonorrhoea particularly when penicillin has failed or is unsuitable. other bacterial infections such as meningitis and other sensitive infections suitable for parenteral antibiotic therapy prophylaxis: prophylaxis of infections in patients with reduced resistance. pre-operative prophylaxis in patients who are at increased risk from infection.

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - cefotaxime sodium (unii: 258j72s7tz) (cefotaxime - unii:n2gi8b1gk7) - cefotaxime 500 mg - cefotaxime for injection usp is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. - lower respiratory tract infections , including pneumonia, caused bystreptococcus pneumoniae (formerlydiplococcus pneumoniae ),streptococcus pyogenes * (group a streptococci) and other streptococci (excluding enterococci, e.g.,enterococcus faecalis ),staphylococcus aureus (penicillinase and non-penicillinase producing),escherichia coli ,klebsiella species,haemophilus influenzae (including ampicillin resistant strains),haemophilus parainfluenzae ,proteus mirabilis ,serratia marcescens *,enterobacter species, indole positiveproteus andpseudomonas species (includingp. aeruginosa ). - genitourinary infections . urinary tract infections caused byenterococcus species,staphylococcus epidermidis ,staphylococcus aureus *, (penicillinase and non-penicillinase producing),citrobacter species,enterobacter species,escherichia coli ,kl

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - cefotaxime sodium (unii: 258j72s7tz) (cefotaxime - unii:n2gi8b1gk7) - cefotaxime 1 g - cefotaxime for injection, usp is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae (formerly diplococcus pneumoniae ), streptococcus pyogenes* (group a streptococci) and other streptococci (excluding enterococci, e.g., enterococcus faecalis ), staphylococcus aureus (penicillinase and non-penicillinase producing), escherichia coli , klebsiella species, haemophilus influenzae (including ampicillin resistant strains), haemophilus parainfluenzae , proteus mirabilis , serratia marcescens* , enterobacter species, indole positive proteus and pseudomonas species (including p. aeruginosa ). (2) genitourinary infections . urinary tract infections caused by enterococcus species, staphylococcus epidermidis , staphylococcus aureus* , (penicillinase and non-penicillinase producing), citrobacter species, enterobac

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - cefotaxime sodium (unii: 258j72s7tz) (cefotaxime - unii:n2gi8b1gk7) - cefotaxime 10 g - cefotaxime for injection, usp is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae (formerly diplococcus pneumoniae ), streptococcus pyogenes* (group a streptococci) and other streptococci (excluding enterococci, e.g., enterococcus faecalis ), staphylococcus aureus (penicillinase and non-penicillinase producing), escherichia coli , klebsiella species, haemophilus influenzae (including ampicillin resistant strains), haemophilus parainfluenzae , proteus mirabilis , serratia marcescens* , enterobacter species, indole positive proteus and pseudomonas species (including p. aeruginosa ). (2) genitourinary infections . urinary tract infections caused by enterococcus species, staphylococcus epidermidis , staphylococcus aureus* , (penicillinase and non-penicillinase producing), citrobacter species, enterobac

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cefotaxime sodium, quantity: 2.096 g - injection, powder for - excipient ingredients: - indications: cefotaxime is indicated for the treatment of the following types of infection when caused by susceptible micro-organisms: infections of the respiratory tract (upper and lower). infections of the urinary tract. septicaemia - concomitant therapy with an aminoglycoside may be instituted prior to isolation of the causative organism. intra-abdominal infection. gonorrhoea (including gonorrhoea caused by beta lactamase producing strains of n.gonorrhoeae). ear, nose and throat infections. skin and skin structure infections. bone and joint infections. meningitis - cefotaxime should be combined with an appropriate alternative antibiotic (ampicillin, chloramphenicol or penicillin g) for initial therapy in children, (excluding neonates) pending the availabiliy of culture and sensitivity results. in adults, the empirical use of cefotaxime should be restricted to patients suspected of having meningitis caused by gram negative enteric bacilli. cefotaxime may be used for the prevention of post-operative infe

United States - English - NLM (National Library of Medicine)

wockhardt usa llc. - cefotaxime sodium (unii: 258j72s7tz) (cefotaxime - unii:n2gi8b1gk7) - cefotaxime 500 mg - treatment cefotaxime for injection, usp is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections , including pneumonia, caused by streptococcus pneumoniae (formerly diplococcus pneumoniae ), streptococcus pyogenes * (group a streptococci) and other streptococci (excluding enterococci, e.g., enterococcus faecalis ), staphylococcus aureus (penicillinase and non-penicillinase producing), escherichia coli , klebsiella species, haemophilus influenzae (including ampicillin resistant strains), haemophilus parainfluenzae , proteus mirabilis , serratia marcescens *, enterobacter species, indole positive proteus and pseudomonas species (including p. aeruginosa ). (2) genitourinary infections . urinary tract infections caused by enterococcus species, staphylococcus epidermidis , staphylococcus aureus *, (penicillinase and non-penicillinase producing), citrobacter species,

Canada - English - Health Canada

hospira healthcare ulc - cefotaxime (cefotaxime sodium) - powder for solution - 250mg - cefotaxime (cefotaxime sodium) 250mg - third generation cephalosporins

Canada - English - Health Canada

hospira healthcare ulc - cefotaxime (cefotaxime sodium) - powder for solution - 500mg - cefotaxime (cefotaxime sodium) 500mg - third generation cephalosporins

Canada - English - Health Canada

hospira healthcare ulc - cefotaxime (cefotaxime sodium) - powder for solution - 1.0g - cefotaxime (cefotaxime sodium) 1.0g - third generation cephalosporins

Canada - English - Health Canada

hospira healthcare ulc - cefotaxime (cefotaxime sodium) - powder for solution - 2.0g - cefotaxime (cefotaxime sodium) 2.0g - third generation cephalosporins